Progress in brain penetration evaluation in drug discovery and development.
about
Dendrimer advances for the central nervous system delivery of therapeuticsThe hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intakePrecision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive AstrocytesNeurovascular unit on a chip: implications for translational applications.In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.Brainpeps: the blood-brain barrier peptide database.Characterization of a novel brain barrier ex vivo insect-based P-glycoprotein screening model.In vivo assessment of the permeability of the blood-brain barrier and blood-retinal barrier to fluorescent indoline derivatives in zebrafish.Dosing in neonates: special considerations in physiology and trial design.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesInhibiting drug efflux transporters improves efficacy of ALS therapeuticsA comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development.Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model.Drug interactions at the blood-brain barrier: fact or fantasy?Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.NanoART, neuroAIDS and CNS drug delivery.From pharmacokinetics to therapeutics.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.L-type calcium channels and psychiatric disorders: A brief review.Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity.Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systemsPhysiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats.Improving the prediction of drug disposition in the brain.Strategies to assess blood-brain barrier penetration.In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life.Overview of experimental models of the blood-brain barrier in CNS drug discovery.Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations.Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.Use of a novel rapid and resource-efficient cassette dosing approach to determine the pharmacokinetics and CNS distribution of small molecule 7-transmembrane receptor allosteric modulators in rat.Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys.Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.Exploring cinnamic acid scaffold: development of promising neuroprotective lipophilic antioxidants
P2860
Q26828423-23C139FF-8970-4483-A8FF-D168BD60F2B2Q26850858-4FB06DDF-7C9A-4405-B931-DCA26A602D1AQ28078621-29303E72-F9AD-4C5B-8D36-29696B0A6DF0Q33643866-B0924DF4-AB38-41D9-A7FA-67070A0C2084Q34058209-560716F7-20AC-4FF4-941F-6E7A9E329F96Q34243408-19643327-14DD-4939-A441-721FF71CCE5EQ34292573-55570B1C-3E7F-46D6-9B23-0EAAF617222DQ34380482-924040B6-A54C-4817-96BE-021270C27033Q34716879-7CE92314-EC12-4FB4-B014-0FF09829971AQ34797004-2C88B510-D5CD-4875-A40A-C95F2FF8C545Q34824777-7538F632-3DE8-4D69-A580-89A604E233E6Q35183619-0E86CA2B-D319-4132-8B79-89A75EF90F53Q37251993-1162324A-2B38-402C-A0D3-68B4D3F0D116Q37271237-8E9DD074-49AE-4BB4-B46D-33DB4DE5FE57Q37311185-B28DB89F-BD15-4558-954A-28B910AD68DCQ37355679-57CAE7C7-88DF-4745-BC18-2EF9914FDEE5Q37362486-E63FBE41-86BB-48A3-B1C4-DCE9FAB9787CQ37422727-6AD56721-A676-43BF-89C4-499BCE89C3F3Q37538776-F1F135ED-2BF8-4164-8567-90F6C3C2B58FQ37550564-A977A8D4-2A03-4ED0-8828-8C0685346F51Q37638755-EFAA7EBD-2086-4436-9615-CEF05D4F763FQ37795701-75FF1D9A-AFD4-4083-898D-EE8C24A7D838Q37872394-3B15A427-C29F-47A5-831C-F06B48804475Q37942472-0506A227-5FDF-4960-BCE3-DC9FC60CEC05Q38010342-702C1131-9FD7-4159-99B4-30F45F2314E1Q38072077-4AF514C7-6AFB-42CE-8070-0FA091A94BE6Q38090672-6A0E2EE8-C342-495D-8FCF-09A9E929E835Q38098252-6C9EAF95-F5C0-46A2-BA6E-C94315BC378CQ38186650-2493A98B-C15E-4C5B-897E-89448A7D6388Q38798039-48EF1ECA-966B-4CED-9820-4AE46418AD80Q39454820-9D471C39-29D4-49CA-9583-6FE669451971Q39754769-F896CB09-0D7F-41CB-B3E8-6534948075DEQ41692430-29409F86-5EF8-40E0-9A93-7FF0AEC5350FQ44297446-F538E30A-E0BE-4299-AD58-A0E860A0C0F4Q47894479-441E83EC-FB91-4CD8-B430-FF9B5C8EFE2AQ48096641-2FCE8EE6-471E-4E05-AF3A-5A441A09FF23Q48854235-F0038706-DDF5-401B-97B4-C5D9EE7FDA65Q48957750-ADC19945-A7D7-4FC1-8D82-856B89DB56DFQ53185668-5F69486A-29F0-4EA2-8A0E-633FE3D02FF5Q56990886-7E24B0E2-EA00-4A41-B551-3037799B12A7
P2860
Progress in brain penetration evaluation in drug discovery and development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progress in brain penetration evaluation in drug discovery and development.
@en
Progress in brain penetration evaluation in drug discovery and development.
@nl
type
label
Progress in brain penetration evaluation in drug discovery and development.
@en
Progress in brain penetration evaluation in drug discovery and development.
@nl
prefLabel
Progress in brain penetration evaluation in drug discovery and development.
@en
Progress in brain penetration evaluation in drug discovery and development.
@nl
P2093
P356
P1476
Progress in brain penetration evaluation in drug discovery and development.
@en
P2093
Bill J Smith
Cuiping Chen
Xingrong Liu
P304
P356
10.1124/JPET.107.130294
P407
P577
2008-01-18T00:00:00Z